These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 36636828)
1. Investigation of the interactions of HSA and SARS-CoV-2 papain-like protease against eugenol for novel COVID-19 drug discovery: spectroscopic and insilico study. Naz F; Khan I; Baammi S; Islam A J Biomol Struct Dyn; 2023 Nov; 41(19):10161-10170. PubMed ID: 36636828 [TBL] [Abstract][Full Text] [Related]
7. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some Amin SA; Ghosh K; Gayen S; Jha T J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618 [TBL] [Abstract][Full Text] [Related]
8. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation. Kumar D; Kumari K; Vishvakarma VK; Jayaraj A; Kumar D; Ramappa VK; Patel R; Kumar V; Dass SK; Chandra R; Singh P J Biomol Struct Dyn; 2021 Aug; 39(13):4671-4685. PubMed ID: 32567995 [TBL] [Abstract][Full Text] [Related]
9. MD simulation and MM/PBSA identifies phytochemicals as bifunctional inhibitors of SARS-CoV-2. Sharma M; Mahto JK; Dhaka P; Neetu N; Tomar S; Kumar P J Biomol Struct Dyn; 2022; 40(22):12048-12061. PubMed ID: 34448684 [TBL] [Abstract][Full Text] [Related]
12. Marine algal antagonists targeting 3CL protease and spike glycoprotein of SARS-CoV-2: a computational approach for anti-COVID-19 drug discovery. Arunkumar M; Gunaseelan S; Kubendran Aravind M; Mohankumar V; Anupam P; Harikrishnan M; Siva A; Ashokkumar B; Varalakshmi P J Biomol Struct Dyn; 2022; 40(19):8961-8988. PubMed ID: 34014150 [TBL] [Abstract][Full Text] [Related]
13. Application of in-silico drug discovery techniques to discover a novel hit for target-specific inhibition of SARS-CoV-2 Mpro's revealed allosteric binding with MAO-B receptor: A theoretical study to find a cure for post-covid neurological disorder. Zaki MEA; Al-Hussain SA; Al-Mutairi AA; Samad A; Masand VH; Ingle RG; Rathod VD; Gaikwad NM; Rashid S; Khatale PN; Burakale PV; Jawarkar RD PLoS One; 2024; 19(1):e0286848. PubMed ID: 38227609 [TBL] [Abstract][Full Text] [Related]
14. Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M Purohit P; Dash JJ; Muya JT; Meher BR J Biomol Struct Dyn; 2023 Jun; 41(9):3900-3913. PubMed ID: 35388744 [TBL] [Abstract][Full Text] [Related]
15. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target. Kundu D; Selvaraj C; Singh SK; Dubey VK J Biomol Struct Dyn; 2021 Jun; 39(9):3428-3434. PubMed ID: 32362243 [TBL] [Abstract][Full Text] [Related]
16. Reporting dinaciclib and theodrenaline as a multitargeted inhibitor against SARS-CoV-2: an Ahmad S; Pasha Km M; Raza K; Rafeeq MM; Habib AH; Eswaran M; Yadav MK J Biomol Struct Dyn; 2023 Jun; 41(9):4013-4023. PubMed ID: 35451934 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies. Abdizadeh R; Hadizadeh F; Abdizadeh T J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354 [TBL] [Abstract][Full Text] [Related]